Opus Genetics, Inc. (IRD)
4.26
-0.18
(-4.05%)
USD |
NASDAQ |
May 19, 16:00
4.26
0.00 (0.00%)
After-Hours: 20:00
Opus Genetics Research and Development Expense (Quarterly) : 10.58M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Keros Therapeutics, Inc. | 16.10M |
| Xilio Therapeutics, Inc. | 19.83M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Amgen, Inc. | 1.719B |